Anthrax Lethal Factor as an Immune Target in Humans and Transgenic Mice and the Impact of HLA Polymorphism on CD4+ T Cell Immunity

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Ascough, Stephanie ^a   Ingram, Rebecca J ^b   Chu, Karen K ^a   Reynolds, Catherine J ^a   Musson, Julie A ^c   Doganay, Mehmet ^d   Metan, Gökhan ^d   Ozkul, Yusuf ^d   Baillie, Les ^e   Sriskandan, Shiranee ^a   Moore, Stephen J ^f   Gallagher, Theresa B ^f   Dyson, Hugh ^g   Williamson, E Diane ^g   Robinson, John H ^c   Maillere, Bernard ^h   Boyton, Rosemary J ^a   Altmann, Daniel M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ERCIYES UNIVERSITY   (Turkey)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^h SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIAL TOXIN; EPITOPE; HLA ANTIGEN;

ADULT; AMINO ACID SEQUENCE; ANIMAL; ANTHRAX; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CHEMISTRY; EPITOPE MAPPING; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; SKIN DISEASES, BACTERIAL; TRANSGENIC MOUSE; YOUNG ADULT;

ADULT; AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CD4-POSITIVE T-LYMPHOCYTES; EPITOPE MAPPING; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNODOMINANT EPITOPES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; POLYMORPHISM, GENETIC; SKIN DISEASES, BACTERIAL; YOUNG ADULT;

EID: 84901661099     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004085     Document Type: Article

References (88)

1. Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ, (2012) An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med 38: 1092-1104 10.1007/s00134-012-2541-0 [doi].
2. Ramsay CN, Stirling A, Smith J, Hawkins G, Brooks T, et al. (2010) An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill 15: pii: 19465.
3. Powell AG, Crozier JE, Hodgson H, Galloway DJ, (2011) A case of septicaemic anthrax in an intravenous drug user. BMC Infect Dis 11: 21 1471-2334-11-21 [pii];10.1186/1471-2334-11-21 [doi].
4. Ascough S, Ingram RJ, Abarra A, Holmes AJ, Maillere B, et al. (2014) Injectional anthrax infection due to heroin use induces strong immunological memory. Journal of Infection 68 (2):: 200-3.
5. Scobie HM, Rainey GJ, Bradley KA, Young JA, (2003) Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A 100: 5170-5174.
6. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA, (2001) Identification of the cellular receptor for anthrax toxin. Nature 414: 225-229.
7. Martchenko M, Jeong SY, Cohen SN, (2010) Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci U S A 107: 15583-15588 1010145107 [pii];10.1073/pnas.1010145107 [doi].
8. Agrawal A, Lingappa J, Leppla SH, Agrawal S, Jabbar A, et al. (2003) Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424: 329-334.
9. Fang H, Xu LX, Chen TY, Cyr JM, et al. (2006) Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production. Journal of Immunology 176: 6155-6161.
10. Joshi SK, Lang GA, Larabee JL, Devera TS, Aye LM, et al. (2009) Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog 5: e1000588.
11. Khan MA, Gallo RM, Brutkiewicz RR, (2010) Anthrax Lethal Toxin Impairs CD1d-Mediated Antigen Presentation by Targeting the ERK1/2 MAPK Pathway. Infect Immun 78 (5):: 1859-63.
12. Baillie LW, (2006) Past, imminent and future human medical countermeasures for anthrax. J Appl Microbiol 101: 594-606.
13. Turnbull PC, (1991) Anthrax vaccines: past, present and future. Vaccine 9: 533-539.
14. Brey RN, (2005) Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 57: 1266-1292.
15. Enstone JE, Wale MC, Nguyen-Van-Tam JS, Pearson JC, (2003) Adverse medical events in British service personnel following anthrax vaccination. Vaccine 21: 1348-1354.
16. Baillie LW, Fowler K, Turnbull PC, (1999) Human immune responses to the UK human anthrax vaccine. J Appl Microbiol 87: 306-308.
17. Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, et al. (2010) Phase I Study of Safety and Immunogenicity of an Escherichia coli-Derived Recombinant Protective Antigen (rPA) Vaccine to Prevent Anthrax in Adults. PLoS ONE 5: e13849.
18. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, et al. (2007) Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 3: 205-211.
19. Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, et al. (2006) Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 24: 5950-5959.
20. Pajewski NM, Parker SD, Poland GA, Ovsyannikova IG, Song W, et al. (2011) The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed. Genes Immun 12: 457-465 gene201115 [pii];10.1038/gene.2011.15 [doi].
21. Pajewski NM, Shrestha S, Quinn CP, Parker SD, Wiener H, et al. (2012) A genome-wide association study of host genetic determinants of the antibody response to Anthrax Vaccine Adsorbed. Vaccine 30: 4778-4784 S0264-410X(12)00736-0 [pii];10.1016/j.vaccine.2012.05.032 [doi].
22. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, et al. (2008) Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300: 1532-1543.
23. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, et al. (2006) Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24: 3654-3660.
24. Little SF, Ivins BE, Webster WM, Fellows PF, Pitt ML, et al. (2006) Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24: 2530-2536.
25. Wattiau P, Govaerts M, Frangoulidis D, Fretin D, Kissling E, et al. (2009) Immunologic response of unvaccinated workers exposed to anthrax, Belgium. Emerg Infect Dis 15: 1637-1640.
26. Kissling E, Wattiau P, China B, Poncin M, Fretin D, et al. (2012) B. anthracis in a wool-processing factory: seroprevalence and occupational risk. Epidemiol Infect 140: 879-886.
27. Wang JY, Roehrl MH, (2005) Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin. Med Immunol 4: 4.
28. Brossier F, Levy M, Mock M, (2002) Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun 70: 661-664.
29. Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, et al. (2004) Anthrax capsule vaccine protects against experimental infection. Vaccine 23: 43-47.
30. Pezard C, Weber M, Sirard JC, Berche P, Mock M, (1995) Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect Immun 63: 1369-1372.
31. Turnbull PC, Leppla SH, Broster MG, Quinn CP, Melling J, (1988) Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 177: 293-303.
32. Ingram RJ, Metan G, Maillere B, Doganay M, Ozkul Y, et al. (2010) Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J Immunol 184: 3814-3821.
33. Blackwell JM, Jamieson SE, Burgner D, (2009) HLA and infectious diseases. Clin Microbiol Rev 2009 Apr;22 (2):: 370-85.
34. Trowsdale J, Knight JC, (2013) Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013 14: 301-23.
35. Stern LJ, Wiley DC, (1994) Antigenic peptide binding by class I and class II histocompatibility proteins. Structure 15: 245-51.
36. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, et al. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19: 2237-2242 10.1002/eji.1830191209 [doi].
37. Pancre V, Georges B, Angyalosi G, Castelli F, Delanoye A, et al. (2002) Novel promiscuous HLA-DQ HIV Nef peptide that induces IFN-gamma-producing memory CD4+ T cells. Clin Exp Immunol 129: 429-437 1934 [pii].
38. Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Matile H, et al. (1988) A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 336: 778-780 10.1038/336778a0 [doi].
39. Sundberg E, Jardetzky TS, (1999) Structural basis for HLA-DQ binding by the streptococcal superantigen SSA. Nat Struct Biol 6: 123-129 10.1038/5809 [doi].
40. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, et al. (1993) Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364: 33-39 10.1038/364033a0 [doi].
41. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, et al. (1996) Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci U S A 93: 734-738.
42. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, et al. (1997) Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol 159: 1362-1373.
43. Quinn CP, Singh Y, Klimpel KR, Leppla SH, (1991) Functional Mapping of Anthrax Toxin Lethal Factor by In-Frame Insertion Mutagenesis. Journal of Biological Chemistry 266: 20124-20130.
44. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M, et al. (2002) Anthrax toxin: a tripartite lethal combination. FEBS Lett 531: 384-388.
45. Glomski IJ, Corre JP, Mock M, Goossens PL, (2007) Cutting Edge: IFN-gamma-producing CD4 T lymphocytes mediate spore-induced immunity to capsulated Bacillus anthracis. J Immunol 178: 2646-2650.
46. Baldari CT, Tonello F, Paccani SR, Montecucco C, (2006) Anthrax toxins: A paradigm of bacterial immune suppression. Trends Immunol 27: 434-440 S1471-4906(06)00207-9 [pii];10.1016/j.it.2006.07.002 [doi].
47. Terra JK, France B, Cote CK, Jenkins A, Bozue JA, et al. (2011) Allelic variation on murine chromosome 11 modifies host inflammatory responses and resistance to Bacillus anthracis. PLoS Pathog 7: e1002469.
48. Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, et al. (2012) Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog 8: e1002638.
49. Terra JK, Cote CK, France B, Jenkins AL, Bozue JA, et al. (2010) Cutting edge: resistance to Bacillus anthracis infection mediated by a lethal toxin sensitive allele of Nalp1b/Nlrp1b. J Immunol 184: 17-20.
50. Boyden ED, Dietrich WF, (2006) Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 38: 240-244.
51. Quinn CP, Sabourin CL, Niemuth NA, et al. (2012) A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection against Inhalation Anthrax in Rhesus Macaques. Clin Vacc Immunol 19: 1730-1745.
52. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, et al. (2001) Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect Immun 69: 4509-4515.
53. Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, et al. (2004) Genetic immunization against anthrax. Vaccine 22: 1604-1608.
54. Hermanson G, Whitlow V, Parker S, Tonsky K, Rusalov D, et al. (2004) A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci U S A 101: 13601-13606.
55. Fish DC, Mahlandt BG, Dobbs JP, Lincoln RE, (1968) Purification and properties of in vitro-produced anthrax toxin components. J Bacteriol 95: 907-918.
56. Kwok WW, Liu AW, Novak EJ, Gebe JA, Ettinger RA, et al. (2000) HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells. J Immunol 164: 4244-4249.
57. Pannifer AD, Wong TY, Schwarzenbacher R, Renatus M, Petosa C, et al. (2001) Crystal structure of the anthrax lethal factor. Nature 414: 229-233.
58. Liang XD, Young JJ, Boone SA, Waugh DS, Duesbery NS, (2004) Involvement of domain II in toxicity of anthrax lethal factor. Journal of Biological Chemistry 279: 52473-52478.
59. Mock M, Roques BP, (2002) Progress in rapid screening of Bacillus anthracis lethal factor activity. Proc Natl Acad Sci U S A 99: 6527-6529.
60. James EA, Bui J, Berger D, Huston L, Roti M, et al. (2007) Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 19: 1291-1301.
61. Hammond SE, Hanna PC, (1998) Lethal factor active-site mutations affect catalytic activity in vitro. Infect Immun 66: 2374-2378.
62. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, et al. (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280: 734-737.
63. Buus S, Sette A, Colon SM, Miles C, Grey HM, (1987) The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 235: 1353-1358.
64. Schaeffer EB, Sette A, Johnson DL, Bekoff MC, Smith JA, et al. (1989) Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc Natl Acad Sci U S A 86: 4649-4653.
65. Weaver JM, Lazarski CA, Richards KA, Chaves FA, Jenks SA, et al. (2008) Immunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design. J Immunol 181: 3039-3048.
66. Lazarski CA, Chaves FA, Jenks SA, Wu S, Richards KA, et al. (2005) The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 23: 29-40.
67. Friedlander AM, Bhatnagar R, Leppla SH, Johnson L, Singh Y, (1993) Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect Immun 61: 245-252.
68. Arora N, Leppla SH, (1993) Residues-1-254 of Anthrax Toxin Lethal Factor Are Sufficient to Cause Cellular Uptake of Fused Polypeptides. Journal of Biological Chemistry 268: 3334-3341.
69. Nguyen ML, Terzyan S, Ballard JD, James JA, Farris AD, (2009) The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun 77: 4714-4723.
70. Baillie LW, Huwar TB, Moore S, Mellado-Sanchez G, Rodriguez L, et al. (2010) An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor. Vaccine 28: 6740-6748.
71. Guidi-Rontani C, Duflot E, Mock M, (1997) Anthrax lethal toxin-induced mitogenic response of human T-cells. FEMS Microbiol Lett 157: 285-289.
72. Weiner MA, Hanna PC, (2003) Macrophage-mediated germination of Bacillus anthracis endospores requires the gerH operon. Infect Immun 71: 3954-3959.
73. Brenneman KE, Doganay M, Akmal A, Goldman S, Galloway DR, et al. (2011) The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax. FEMS Immunol Med Microbiol 62: 164-172.
74. Siew LK, Beech JT, Thompson SJ, Elson CJ, (1998) Effect of T-helper cytokine environment on specificity of T-cell responses to mycobacterial 65,000 MW heat-shock protein. Immunology 93: 493-497.
75. Paccani SR, Tonello F, Ghittoni R, Natale M, Muraro L, et al. (2005) Anthrax toxins suppress T lymphocyte activation by disrupting antigen receptor signaling. Journal of Experimental Medicine 201: 325-331.
76. Fang H, Cordoba-Rodriguez R, Lankford CSR, Frucht DM, (2005) Anthrax lethal toxin blocks MAPK kinase-dependent IL-2 production in CD4(+) T cells. Journal of Immunology 174: 4966-4971.
77. Comer JE, Chopra AK, Peterson JW, Konig R, (2005) Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo. Infect Immun 73: 8275-8281.
78. Paccani SR, Benagiano M, Capitani N, Zornetta I, et al. (2009) The Adenylate Cyclase Toxins of Bacillus anthracis and Bordetella pertussis Promote Th2 Cell Development by Shaping T Cell Antigen Receptor Signaling. Plos Pathogens 5 5 (3):: e1000325 doi:10.1371.
79. Paccani SR, Benagiano M, Savino MT, Finetti F, Tonello F, et al. (2011) The adenylate cyclase toxin of Bacillus anthracis is a potent promoter of T(H)17 cell development. J Allergy Clin Immunol 127: 1635-1637.
80. Baillie L, Townend T, Walker N, Eriksson U, Williamson D, (2004) Characterization of the human immune response to the UK anthrax vaccine. FEMS Immunol Med Microbiol 42: 267-270.
81. Altmann DM, Takacs K, Trowsdale J, Elliott JI, (1993) Mouse mammary tumor virus-mediated T-cell receptor negative selection in HLA-DRA transgenic mice. Hum Immunol 37: 149-156.
82. Ellmerich S, Mycko M, Takacs K, Waldner H, Wahid FN, et al. (2005) High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 174: 1938-1946 174/4/1938 [pii].
83. Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, et al. (2004) Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur J Immunol 34: 1839-1848 10.1002/eji.200324044 [doi].
84. Ito K, Bian HJ, Molina M, Han J, Magram J, et al. (1996) HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 183: 2635-2644.
85. Boyton RJ, Lohmann T, Londei M, Kalbacher H, Halder T, et al. (1998) Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice. Int Immunol 10: 1765-1776.
86. Kaushansky N, Altmann DM, Ascough S, David CS, Lassmann H, et al. (2009) HLA-DQB1*0602 determines disease susceptibility in a new "humanized" multiple sclerosis model in HLA-DR15 (DRB1*1501;DQB1*0602) transgenic mice. J Immunol 183: 3531-3541 jimmunol.0900784 [pii];10.4049/jimmunol.0900784 [doi].
87. Texier C, Pouvelle S, Busson M, Herve M, Charron D, et al. (2000) HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 164: 3177-3184 ji_v164n6p3177 [pii].
88. Laird MW, Zukauskas D, Johnson K, Sampey GC, Olsen H, et al. (2004) Production and purification of Bacillus anthracis protective antigen from Escherichia coli. Protein Expr Purif 38: 145-152 S1046-5928(04)00282-7 [pii];10.1016/j.pep.2004.08.007 [doi].